Jazz Pharmaceuticals Plc (NASDAQ: JAZZ)
Jazz Pharmaceuticals Plc Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Jazz Pharmaceuticals Plc Company Info
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
News & Analysis
Prediction: These Could Be the Best-Performing Cannabis Stocks Through 2030
These two businesses may be sound, but generating returns in this industry has been tough, with no light at the end of the tunnel.
My Top Cannabis Stock to Buy in 2023 and Hold For 10 Years
The cannabis sector has been disappointing in recent years, but this company stands out.
2 Cannabis Stocks That Could Make You Richer
These two stocks could grow like a weed in the next five years and beyond.
2 Stocks That Beat the Market in 2022 and That Analysts Think Can Go Higher
There are still plenty of growth opportunities left for these businesses.
2 Dirt Cheap Growth Stocks to Buy and Hold for Years
In the long run, these stocks could deliver great returns.
3 Top Marijuana Stocks to Buy for the Long Haul
The three have the financial strength to benefit from increased cannabis sales and cannabis therapies.
3 Top Pot Stocks to Watch in September
All three of these cannabis-related stocks turned profits last quarter and have had strong revenue growth.
2 Growth Stocks That Are Beating Amazon Without Breaking a Sweat
They're both cornering specialized markets and growing aggressively in the process.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.